Innovative drugs for inflammation and autoimmune disease
Accropeutics (Accro Bioscience) is a Suzhou, China-based clinical-stage biotech focused on inflammation, autoimmune diseases, and cancer. Its lead asset AC-101, a RIPK2 inhibitor, received FDA IND clearance for Phase II in moderate-to-severe ulcerative colitis. A secondary asset AC-201 targets TYK2/JAK1 for non-infectious uveitis. The company secured $12M in Series B Plus financing in March 2025.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountMay 2026
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
